Supply and Operational Risks from the Spread of COVID-19
First written in FY2020. 11 of 14 entries say "Restated". Latest entry: FY2025.
The whole theme swung hardest in 2020: 102 of 175 companies on the "Worse" side.
- FY2025DroppedAnnual report
「At medical facilities, the number of surgeries and examinations is showing signs of recovery to pre-pandemic levels. However, the environment surrounding the healthcare-related industry remains difficult due to the impact of soaring material costs, chronic shortages of healthcare professionals and other factors.」
Rather than describing supply and operating risks from the spread of COVID-19 as a separate risk, the company has positioned the number of surgeries and examinations as trending toward recovery to pre-pandemic levels. - FY2024-Q3RestatedAnnual report
「During the cumulative third quarter of the current consolidated fiscal year, there were no new business or other risks, nor any material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company has reconfirmed the supply and operating risks from the spread of COVID-19 through a comprehensive statement that there have been no new occurrences or material changes. - FY2024-Q1RestatedAnnual report
「During the cumulative first quarter under review, there were no new business or other risks, nor any material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
The company has reconfirmed the supply and operating risks from the spread of COVID-19 through a comprehensive statement that there have been no material changes. - FY2023-Q2RestatedAnnual report
「During the cumulative second quarter of the current consolidated fiscal year, there were no new business or other risks, nor any material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company has reconfirmed the supply and operating risks from the spread of COVID-19 through a comprehensive statement that there have been no material changes. - FY2023-Q1RestatedAnnual report
「During the cumulative first quarter under review, there were no new business or other risks, nor any material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
The company has reconfirmed the supply and operating risks from the spread of COVID-19 through a comprehensive statement that there have been no material changes. - FY2022RestatedAnnual report
「Our group is responding with the utmost attention to maintaining stable product supplies and business continuity even if COVID-19 continues to spread. In sales activities, we are prioritizing infection prevention, taking the utmost measures to prevent infections among group employees, and continuing operations.」
In response to supply and operating risks from the spread of COVID-19, the company continues to maintain stable product supplies and business continuity and take infection prevention measures for employees. - FY2022-Q3RestatedAnnual report
「In the healthcare industry to which the Group belongs, the six-month cumulative period generally remained on a recovery trend, reflecting the reaction to the previous year's conditions. In the third quarter, the number of surgeries and examinations showed signs of recovery as the spread of infections subsided, although the effects of COVID-19 continued.」
While the number of surgeries and examinations in the healthcare-related industry is trending toward recovery, the company has reconfirmed that the impact of infectious diseases continues. - FY2022-Q2RestatedAnnual report
「Against this backdrop, our group has partially refrained from sales activities out of consideration for infection risks at medical facilities, while responding with attention to business continuity so that no problems arise with product supplies and other matters.」
The company continues to partially refrain from sales activities in view of infection risks at medical facilities and continues measures addressing product supplies and business continuity. - FY2022-Q1RestatedAnnual report
「Against this backdrop, our group has continued to partially refrain from sales activities out of consideration for infection risks at medical facilities, while responding with attention to business continuity so that no problems arise with product supplies and other matters.」
The company continues to partially refrain from sales activities in view of infection risks and continues measures to maintain product supplies and business continuity. - FY2021RestatedAnnual report
「Our group is responding with the utmost attention to maintaining stable product supplies and business continuity even as COVID-19 continues to spread. In sales activities, we have made infection prevention our highest priority, partially refrained from sales activities, and continued operations while taking the utmost measures to prevent infections among group employees.」
In response to supply and operating risks from the spread of COVID-19, the company continues to maintain stable product supplies, implement infection prevention measures and partially refrain from sales activities. - FY2021-Q3RestatedAnnual report
「Against this backdrop, our group has partially refrained from sales activities out of consideration for infection risks at medical facilities. Regarding product supplies, we have worked to implement infection prevention measures at production sites so that no problems arise even as society is disrupted by COVID-19.」
The company continues to partially refrain from sales activities in view of infection risks and continues infection prevention measures at production sites to maintain product supplies. - FY2021-Q2RestatedAnnual report
「Against this backdrop, our group has partially refrained from sales activities out of consideration for infection risks at medical facilities. Regarding product supplies, we have worked to implement infection prevention measures at production sites so that no problems arise even as society is disrupted by COVID-19.」
While the company continues to partially refrain from sales activities out of consideration for infection risks at medical facilities, it continues to implement infection prevention measures at production sites to maintain product supplies. - FY2021-Q1MaterialisedAnnual report
「Against this backdrop, our group has partially refrained from sales activities out of consideration for infection risks at medical facilities. Regarding product supplies, we have worked to thoroughly implement infection prevention measures at production sites so that no problems arise even as society is disrupted by COVID-19.」
The company states that it actually had to partially refrain from sales activities due to the impact of COVID-19. At the same time, it has thoroughly implemented infection prevention measures at production sites to avoid problems with product supplies. - FY2020First statedAnnual report
「Regarding COVID-19, which is spreading globally, sales have been somewhat weak recently, but overall there has been no significant impact. However, if infections spread again in the future and the time required for containment is longer than expected, production and shipment of products could be disrupted by delays or interruptions in the supply of parts and other items, or temporary suspension of operations due to infections among employees.」
The company states that the impact of COVID-19 is limited at present, while identifying delays or interruptions in parts supplies and operational shutdowns due to employee infections as new risks.